Engineered immune cells for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new type of cell therapy that uses your own immune cells, modified to target proteins found on some stomach cancer cells. It is for people with advanced stomach cancer that has not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your stomach cancer is advanced (stage IV) and has progressed after standard treatments, or you have chosen not to receive standard therapy.
- Your tumor must have certain markers (AXL and CD73) that can be detected by a lab test.
- You are generally able to care for yourself (ECOG score 0 or 1).
- You have at least one measurable tumor lesion that is at least 1 cm in size.
- Your blood counts and organ function are within acceptable ranges.
- You have not had certain prior treatments or conditions that would make this trial unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares three different treatment combinations for advanced stomach cancer that hasn't spread to the brain and is HER2-negative. It includes an immunotherapy drug (sintilimab) with different chemotherapy backbones, and one option adds a targeted therapy (lenvatinib). The goal is to see which combination works best and has acceptable side effects.
This trial tests a combination of fecal microbiota transplant (FMT), chemotherapy (SOX), and an immunotherapy drug (Sintilimab) as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
This early-phase trial tests a new type of immune cell therapy (TCRx T cells) for advanced stomach cancer that has not responded to standard chemotherapy. The goal is to see if these specially engineered cells can help your body fight the cancer.
This trial tests a special type of immune cell therapy for people with advanced gastric cancer. The treatment uses your own immune cells that are specially trained to find and attack cancer cells. It may help when standard treatments have stopped working.
This trial tests a new treatment combining an injection (XH001) with specially made immune cells (T-cells) that target your tumor's unique markers. It's for people with advanced stomach cancer who have not responded to standard therapies.
This phase 3 study compares two versions of a first-time treatment for HER2-negative advanced stomach or gastroesophageal cancer, both including immunotherapy (sintilimab). It looks for a safer or more effective way to slow cancer growth or improve outcomes.
Hear when a new Stage IV Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.